Pancreatic cancer stromal biology and therapy

Genes and Diseases

Volumn 2, Issue 2, 2015, Pages 133-143

  Xie, Dacheng ^a   Xie, Keping ^b  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cytokines; Growth factors; Immunology; Stroma; Therapy; Transcriptional factors

Indexed keywords

GROWTH FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; BIOLOGICAL ACTIVITY; CANCER GROWTH; CANCER THERAPY; CELL COMPONENT; EPITHELIAL MESENCHYMAL TRANSITION; FAMILIAL CANCER; HUMAN; MESENCHYMAL STEM CELL; NONHUMAN; PANCREAS CANCER; PANCREAS TUMOR; PANCREATITIS; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STROMA; STROMA CELL;

ANIMALIA;

EID: 84978138206     PISSN: None     EISSN: 23523042     Source Type: Journal    
DOI: 10.1016/j.gendis.2015.01.002     Document Type: Review

References (142)

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015, 65(1):5-29.
2. DeSantis C.E., Lin C.C., Mariotto A.B., et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin 2014, 64:252-271.
3. Ryan D.P., Hong T.S., Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med 2014, 371:1039-1049.
4. Bednar F., Simeone D.M. Recent advances in pancreatic surgery. Curr Opin Gastroenterol 2014, 30:518-523.
5. Karachristos A., Esnaola N.F. Surgical management of pancreatic neoplasms: what's new?. Curr Gastroenterol Rep 2014, 16:397.
6. Bliss L.A., Witkowski E.R., Yang C.J., Tseng J.F. Outcomes in operative management of pancreatic cancer. J Surg Oncol 2014, 110:592-598.
7. McCarroll J.A., Naim S., Sharbeen G., et al. Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Front Physiol 2014, 5:141.
8. Xie K., Wei D., Huang S. Transcriptional anti-angiogenesis therapy of human pancreatic cancer. Cytokine Growth Factor Rev 2006, 17:147-156.
9. Huang C., Xie K. Crosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis. Cytokine Growth Factor Rev 2012, 23:25-35.
10. Quan M., Wang P., Cui J., Gao Y., Xie K. The roles of FOXM1 in pancreatic stem cells and carcinogenesis. Mol Cancer 2013, 12:159.
11. Haddad A., Kowdley G.C., Pawlik T.M., Cunningham S.C. Hereditary pancreatic and hepatobiliary cancers. Int J Surg Oncol 2011, 2011:154673.
12. Brentnall T.A. Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol 2005, 6:437-445.
13. Kimura W., Kuroda A., Makuuchi M. Problems in the diagnosis and treatment of a so-called mucin-producing tumor of the pancreas. Pancreas 1998, 16:363-369.
14. Neesse A., Michl P., Frese K.K., et al. Stromal biology and therapy in pancreatic cancer. Gut 2011, 60:861-868.
15. Cowan R.W., Maitra A. Genetic progression of pancreatic cancer. Cancer J 2014, 20:80-84.
16. Rustgi A.K. Familial pancreatic cancer: genetic advances. Genes Dev 2014, 28:1-7.
17. Wood L.D., Hruban R.H. Pathology and molecular genetics of pancreatic neoplasms. Cancer J 2012, 18:492-501.
18. Kindler H.L., Ioka T., Richel D.J., et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011, 12:256-262.
19. Stromnes I.M., DelGiorno K.E., Greenberg P.D., Hingorani S.R. Stromal reengineering to treat pancreas cancer. Carcinogenesis 2014, 35:1451-1460.
20. Neesse A., Krug S., Gress T.M., Tuveson D.A., Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther 2013, 7:33-43.
21. Chu G.C., Kimmelman A.C., Hezel A.F., DePinho R.A. Stromal biology of pancreatic cancer. J Cell Biochem 2007, 101:887-907.
22. McCleary-Wheeler A.L., McWilliams R., Fernandez-Zapico M.E. Aberrant signaling pathways in pancreatic cancer: a two compartment view. Mol Carcinog 2012, 51:25-39.
23. Brugge W.R., Lauwers G.Y., Sahani D., Fernandez-del Castillo C., Warshaw A.L. Cystic neoplasms of the pancreas. N Engl J Med 2004, 351:1218-1226.
24. Maitra A., Fukushima N., Takaori K., Hruban R.H. Precursors to invasive pancreatic cancer. Adv Anat Pathol 2005, 12:81-91.
25. Bardeesy N., DePinho R.A. Pancreatic cancer biology and genetics. Nat Rev Cancer 2002, 2:897-909.
26. Heinmoller E., Dietmaier W., Zirngibl H., et al. Molecular analysis of microdissected tumors and preneoplastic intraductal lesions in pancreatic carcinoma. Am J Pathol 2000, 157:83-92.
27. Yamano M., Fujii H., Takagaki T., Kadowaki N., Watanabe H., Shirai T. Genetic progression and divergence in pancreatic carcinoma. Am J Pathol 2000, 156:2123-2133.
28. Klimstra D.S., Longnecker D.S. K-ras mutations in pancreatic ductal proliferative lesions. Am J Pathol 1994, 145:1547-1550.
29. Rozenblum E., Schutte M., Goggins M., et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997, 57:1731-1734.
30. Jones S., Zhang X., Parsons D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
31. Kim Y., Han D., Min H., Jin J., Yi E.C., Kim Y. Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines. Mol Cells 2014, 37:888-898.
32. Pilarsky C., Grutzmann R. Genomics of pancreatic ductal adenocarcinoma. Hepatobiliary Pancreat Dis Int 2014, 13:381-385.
33. Caba O., Prados J., Ortiz R., et al. Transcriptional profiling of peripheral blood in pancreatic adenocarcinoma patients identifies diagnostic biomarkers. Dig Dis Sci 2014, 59:2714-2720.
34. Lili L.N., Matyunina L.V., Walker L.D., Daneker G.W., McDonald J.F. Evidence for the importance of personalized molecular profiling in pancreatic cancer. Pancreas 2014, 43:198-211.
35. Shain A.H., Salari K., Giacomini C.P., Pollack J.R. Integrative genomic and functional profiling of the pancreatic cancer genome. BMC Genomics 2013, 14:624.
36. Zhang G., He P., Tan H., et al. Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res 2013, 19:4983-4993.
37. Chen J., Wu W., Chen L., et al. Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of complement C3 and alpha-2-HS-glycoprotein. Pancreatology 2013, 13:290-297.
38. Bond T. Identification of chemosensitive pancreatic cancer with gene profiling. Biomark Med 2013, 7:200.
39. Brandi J., Dando I., Palmieri M., Donadelli M., Cecconi D. Comparative proteomic and phosphoproteomic profiling of pancreatic adenocarcinoma cells treated with CB1 or CB2 agonists. Electrophoresis 2013, 34:1359-1368.
40. Kong X., Li L., Li Z., Xie K. Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implications. Cytokine Growth Factor Rev 2012, 23:343-356.
41. Birnstingl M. A study of pancreatography. Br J Surg 1959, 47:128-139.
42. Kozuka S., Sassa R., Taki T., et al. Relation of pancreatic duct hyperplasia to carcinoma. Cancer 1979, 43:1418-1428.
43. Petersen O.W., Ronnov-Jessen L., Howlett A.R., Bissell M.J. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 1992, 89:9064-9068.
44. Froeling F.E., Mirza T.A., Feakins R.M., et al. Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells. Am J Pathol 2009, 175:636-648.
45. Cousin B., Ravet E., Poglio S., et al. Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both invitro and invivo. PLoS One 2009, 4:e6278.
46. Gupte A.R., Forsmark C.E. Chronic pancreatitis. Curr Opin Gastroenterol 2014, 30:500-505.
47. Hyun J.J., Lee H.S. Experimental models of pancreatitis. Clin Endosc 2014, 47:212-216.
48. Issa Y., Bruno M.J., Bakker O.J., et al. Treatment options for chronic pancreatitis. Nat Rev Gastroenterol Hepatol 2014, 11:556-564.
49. Pinho A.V., Chantrill L., Rooman I. Chronic pancreatitis: a path to pancreatic cancer. Cancer Lett 2014, 345:203-209.
50. Kloppel G. Chronic pancreatitis, pseudotumors and other tumor-like lesions. Mod Pathol 2007, 20:113-131.
51. Whitcomb D.C. Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 2004, 287:G315-G319.
52. Malka D., Hammel P., Maire F., et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002, 51:849-852.
53. Whitcomb D.C., Pogue-Geile K. Pancreatitis as a risk for pancreatic cancer. Gastroenterol Clin North Am 2002, 31:663-678.
54. Rhim A.D., Mirek E.T., Aiello N.M., et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148:349-361.
55. Whitcomb D.C., Gorry M.C., Preston R.A., et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996, 14:141-145.
56. Hwang R.F., Moore T., Arumugam T., et al. Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res 2008, 68:918-926.
57. Xu Z., Vonlaufen A., Phillips P.A., et al. Role of pancreatic stellate cells in pancreatic cancer metastasis. Am J Pathol 2010, 177:2585-2596.
58. Li Z., Jia Z., Gao Y., et al. Activation of Vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemesss. Clin Cancer Res 2015, 21(4):844-853.
59. Özdemir B.C., Pentcheva-Hoang T., Carstens J.L., et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014, 25:719-734.
60. Studeny M., Marini F.C., Dembinski J.L., et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004, 96:1593-1603.
61. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J., Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002, 62:3603-3608.
62. Kallifatidis G., Beckermann B.M., Groth A., et al. Improved lentiviral transduction of human mesenchymal stem cells for therapeutic intervention in pancreatic cancer. Cancer Gene Ther 2008, 15:231-240.
63. Ghaedi M., Soleimani M., Taghvaie N.M., et al. Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors. J Gene Med 2011, 13:171-180.
64. Ronnov-Jessen L., Petersen O.W., Koteliansky V.E., Bissell M.J. The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 1995, 95:859-873.
65. Tomasek J.J., Gabbiani G., Hinz B., Chaponnier C., Brown R.A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 2002, 3:349-363.
66. Udagawa T., Puder M., Wood M., Schaefer B.C., D'Amato R.J. Analysis of tumor-associated stromal cells using SCID GFP transgenic mice: contribution of local and bone marrow-derived host cells. FASEB J 2006, 20:95-102.
67. Ogawa M., LaRue A.C., Drake C.J. Hematopoietic origin of fibroblasts/myofibroblasts: Its pathophysiologic implications. Blood 2006, 108:2893-2896.
68. Spaeth E.L., Dembinski J.L., Sasser A.K., et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4:e4992.
69. Nakamizo A., Marini F., Amano T., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005, 65:3307-3318.
70. Hung S.C., Deng W.P., Yang W.K., et al. Mesenchymal stem cell targeting of microscopic tumors and tumor stroma development monitored by noninvasive invivo positron emission tomography imaging. Clin Cancer Res 2005, 11:7749-7756.
71. Karnoub A.E., Dash A.B., Vo A.P., et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557-563.
72. Faouzi S., Le Bail B., Neaud V., et al. Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an invivo and invitro study. J Hepatol 1999, 30:275-284.
73. Powell D.W., Mifflin R.C., Valentich J.D., Crowe S.E., Saada J.I., West A.B. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol 1999, 277:C1-C9.
74. Phan S.H. The myofibroblast in pulmonary fibrosis. Chest 2002, 122:286S-289S.
75. Desmouliere A., Darby I.A., Gabbiani G. Normal and pathologic soft tissue remodeling: role of the myofibroblast, with special emphasis on liver and kidney fibrosis. Lab Invest 2003, 83:1689-1707.
76. Petersen O.W., Nielsen H.L., Gudjonsson T., et al. Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma. Am J Pathol 2003, 162:391-402.
77. Lee E.H., Joo C.K. Role of transforming growth factor-beta in transdifferentiation and fibrosis of lens epithelial cells. Invest Ophthalmol Vis Sci 1999, 40:2025-2032.
78. Oldfield M.D., Bach L.A., Forbes J.M., et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001, 108:1853-1863.
79. Li J.H., Wang W., Huang X.R., et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol 2004, 164:1389-1397.
80. Nightingale J., Patel S., Suzuki N., et al. Oncostatin M, a cytokine released by activated mononuclear cells, induces epithelial cell-myofibroblast transdifferentiation via Jak/Stat pathway activation. J Am Soc Nephrol 2004, 15:21-32.
81. Willis B.C., Liebler J.M., Luby-Phelps K., et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 2005, 166:1321-1332.
82. Kim K.K., Kugler M.C., Wolters P.J., et al. Alveolar epithelial cell mesenchymal transition develops invivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006, 103:13180-13185.
83. Selman M., Pardo A. Role of epithelial cells in idiopathic pulmonary fibrosis: from innocent targets to serial killers. Proc Am Thorac Soc 2006, 3:364-372.
84. Gudjonsson T., Adriance M.C., Sternlicht M.D., Petersen O.W., Bissell M.J. Myoepithelial cells: their origin and function in breast morphogenesis and neoplasia. J Mammary Gland Biol Neoplasia 2005, 10:261-272.
85. Moinfar F., Man Y.G., Arnould L., Bratthauer G.L., Ratschek M., Tavassoli F.A. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 2000, 60:2562-2566.
86. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29:15-18.
87. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003, 3:643-651.
88. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990, 82:4-6.
89. Wang R., Chadalavada K., Wilshire J., et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833.
90. Ricci-Vitiani L., Pallini R., Biffoni M., et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828.
91. Vogelmann R., Ruf D., Wagner M., Adler G., Menke A. Effects of fibrogenic mediators on the development of pancreatic fibrosis in a TGF-beta1 transgenic mouse model. Am J Physiol Gastrointest Liver Physiol 2001, 280:G164-G172.
92. Lohr M., Schmidt C., Ringel J., et al. Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res 2001, 61:550-555.
93. Bardeesy N., Cheng K.H., Berger J.H., et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006, 20:3130-3146.
94. Duda D.G., Sunamura M., Lefter L.P., et al. Restoration of SMAD4 by gene therapy reverses the invasive phenotype in pancreatic adenocarcinoma cells. Oncogene 2003, 22:6857-6864.
95. Schwarte-Waldhoff I., Volpert O.V., Bouck N.P., et al. Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis. Proc Natl Acad Sci USA 2000, 97:9624-9629.
96. Aoki H., Ohnishi H., Hama K., et al. Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines. Am J Physiol Cell Physiol 2007, 292:C259-C268.
97. Levy L., Hill C.S. Smad4 dependency defines two classes of transforming growth factor β (TGF-β) target genes and distinguishes TGF-β-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol Cell Biol 2005, 25:8108-8125.
98. Melisi D., Ishiyama S., Sclabas G.M., et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol Cancer Ther 2008, 7:829-840.
99. Medicherla S., Li L., Ma J.Y., et al. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. Anticancer Res 2007, 27:4149-4157.
100. Schlingensiepen K.H., Schlingensiepen R., Steinbrecher A., et al. Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev 2006, 17:129-139.
101. Hoch R.V., Soriano P. Roles of PDGF in animal development. Development 2003, 130:4769-4784.
102. Blaine S.A., Ray K.C., Branch K.M., Robinson P.S., Whitehead R.H., Means A.L. Epidermal growth factor receptor regulates pancreatic fibrosis. Am J Physiol Gastrointest Liver Physiol 2009, 297:G434-G441.
103. Dong J., Grunstein J., Tejada M., et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004, 23:2800-2810.
104. Yu J., Liu X.W., Kim H.R. Platelet-derived growth factor (PDGF) receptor-alpha-activated c-Jun NH2-terminal kinase-1 is critical for PDGF-induced p21WAF1/CIP1 promoter activity independent of p53. J Biol Chem 2003, 278:49582-49588.
105. Xie K., Abbruzzese J.L. Developmental biology informs cancer: the emerging role of the hedgehog signaling pathway in upper gastrointestinal cancers. Cancer Cell 2003, 4:245-247.
106. Teglund S., Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 2010, 1805:181-208.
107. Thayer S.P., di Magliano M.P., Heiser P.W., et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425:851-856.
108. Berman D.M., Karhadkar S.S., Maitra A., et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003, 425:846-851.
109. Feldmann G., Dhara S., Fendrich V., et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007, 67:2187-2196.
110. Yauch R.L., Gould S.E., Scales S.J., et al. A paracrine requirement for hedgehog signalling in cancer. Nature 2008, 455:406-410.
111. Tian H., Callahan C.A., DuPree K.J., et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci USA 2009, 106:4254-4259.
112. Bailey J.M., Swanson B.J., Hamada T., et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin Cancer Res 2008, 14:5995-6004.
113. Olive K.P., Jacobetz M.A., Davidson C.J., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
114. Hu W.G., Liu T., Xiong J.X., Wang C.Y. Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells. Acta Pharmacol Sin 2007, 28:1224-1230.
115. Kelsen D.P., Portenoy R., Thaler H., Tao Y., Brennan M. Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Surgery 1997, 122:53-59.
116. Pelaez-Luna M., Takahashi N., Fletcher J.G., Chari S.T. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 2007, 102:2157-2163.
117. Szafranska A.E., Doleshal M., Edmunds H.S., et al. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 2008, 54:1716-1724.
118. Li A., Omura N., Hong S.M., et al. Pancreatic cancers epigenetically silence SIP1 and hypomethylate and overexpress miR-200a/200b in association with elevated circulating miR-200a and miR-200b levels. Cancer Res 2010, 70:5226-5237.
119. Vincent A., Herman J., Schulick R., Hruban R.H., Goggins M. Pancreatic cancer. Lancet 2011, 378:607-620.
120. Pilarsky C., Ammerpohl O., Sipos B., et al. Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profiling. J Cell Mol Med 2008, 12:2823-2835.
121. Binkley C.E., Zhang L., Greenson J.K., et al. The molecular basis of pancreatic fibrosis: common stromal gene expression in chronic pancreatitis and pancreatic adenocarcinoma. Pancreas 2004, 29:254-263.
122. Allinen M., Beroukhim R., Cai L., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
123. Sultana A., Tudur Smith C., Cunningham D., et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007, 96:1183-1190.
124. Huguet F., Andre T., Hammel P., et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007, 25:326-331.
125. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 15:2403-2413.
126. Ueda S., Ogata S., Tsuda H., et al. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004, 29:e1-e8.
127. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966.
128. Furukawa T., Duguid W.P., Kobari M., Matsuno S., Tsao M.S. Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol 1995, 147:889-895.
129. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
130. Kindler H.L., Niedzwiecki D., Hollis D., et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010, 28:3617-3622.
131. Van Cutsem E., Vervenne W.L., Bennouna J., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009, 27:2231-2237.
132. Bramhall S.R., Neoptolemos J.P., Stamp G.W., Lemoine N.R. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol 1997, 182:347-355.
133. Bramhall S.R., Rosemurgy A., Brown P.D., Bowry C., Buckels J.A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001, 19:3447-3455.
134. Bramhall S.R., Schulz J., Nemunaitis J., Brown P.D., Baillet M., Buckels J.A. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002, 87:161-167.
135. Moore M.J., Hamm J., Dancey J., et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:3296-3302.
136. Infante J.R., Matsubayashi H., Sato N., et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007, 25:319-325.
137. Nyman D.W., Campbell K.J., Hersh E., et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005, 23:7785-7793.
138. Von Hoff D.D., Ramanathan R.K., Borad M.J., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011, 29:4548-4554.
139. Borazanci E., Von Hoff D.D. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Expert Rev Gastroenterol Hepatol 2014, 8:739-747.
140. Porter C.E., Waddell J.A., Solimando D.A. Nab-paclitaxel plus gemcitabine regimen for pancreatic Cancer. Hosp Pharm 2014, 49:18-22.
141. Von Hoff D.D., Ervin T., Arena F.P., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013, 369:1691-1703.
142. Frese K.K., Neesse A., Cook N., et al. nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov 2012, 2:260-269.